Aspen Pharmacare EBITDA 2017-2023 | APNHY
Aspen Pharmacare annual and quarterly EBITDA history from 2017 to 2023. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Aspen Pharmacare EBITDA for the quarter ending June 30, 2023 was $M, a NAN% increase year-over-year.
- Aspen Pharmacare EBITDA for the twelve months ending June 30, 2023 was $0M, a NAN% increase year-over-year.
- Aspen Pharmacare 2023 annual EBITDA was $0.542B, a 20.67% decline from 2022.
- Aspen Pharmacare 2022 annual EBITDA was $0.683B, a 20.11% increase from 2021.
- Aspen Pharmacare 2021 annual EBITDA was $0.569B, a 1.97% increase from 2020.
Aspen Pharmacare Annual EBITDA
(Millions of US $) |
| 2023 |
$542 |
| 2022 |
$683 |
| 2021 |
$569 |
| 2020 |
$558 |
| 2019 |
$429 |
| 2018 |
$829 |
| 2017 |
$706 |
| 2016 |
$708 |
| 2015 |
$ |
Aspen Pharmacare Quarterly EBITDA
(Millions of US $) |
| 2023-06-30 |
|
| 2022-06-30 |
|
| 2021-12-31 |
|
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-06-30 |
|
| 2018-12-31 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.038B |
$2.296B |
|
Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.
|
